Perception of bronchial obstruction in asthmatic patients. Relationship with bronchial eosinophilic inflammation and epithelial damage and effect of corticosteroid treatment.
PDF (1.8M)
Journal: 1995/August - Journal of Clinical Investigation
ISSN: 0021-9738
Abstract:
We studied the perception of bronchoconstriction in asthmatic subjects who were randomly treated with inhaled beta 2 agonist given either alone (n = 9) or associated with inhaled corticosteroids (n = 9). Methacholine and bradykinin challenges, bronchoalveolar lavage, and bronchial biopsies were performed in all subjects. After each dose of agonist, breathlessness was assessed using a visual analog scale (VAS) and the forced expiratory volume in 1 s (FEV1) was measured. The relationship between VAS scores and FEV1 and the slope of the regression line of VAS scores on the corresponding FEV1 (VAS/FEV1 slope) were analyzed for each agonist. Subjects without corticosteroids had good perception of methacholine but poor perception of bradykinin-induced bronchoconstriction. In subjects with corticosteroids, bronchoconstriction was well perceived whatever the agonist. VAS/FEV1 slopes for bradykinin but not for methacholine correlated negatively with the magnitude of eosinophilic inflammation in airway mucosa. VAS/FEV1 slopes for each agonist correlated positively with the percentage of basement membrane covered by airway epithelium. We conclude that in asthmatic patients perception of bronchoconstriction is related to eosinophilic inflammation and to epithelial damage in airways and that corticosteroid treatment is associated with improved perception of bronchoconstriction induced by bradykinin, a mediator endogenously produced in asthma.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(12)
References
(45)
Diseases
(1)
Conditions
(1)
Chemicals
(3)
Organisms
(1)
Processes
(1)
Anatomy
(3)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
J Clin Invest 96(1): 12-21
PMID: 7615781

Perception of bronchial obstruction in asthmatic patients. Relationship with bronchial eosinophilic inflammation and epithelial damage and effect of corticosteroid treatment.

Abstract

We studied the perception of bronchoconstriction in asthmatic subjects who were randomly treated with inhaled beta 2 agonist given either alone (n = 9) or associated with inhaled corticosteroids (n = 9). Methacholine and bradykinin challenges, bronchoalveolar lavage, and bronchial biopsies were performed in all subjects. After each dose of agonist, breathlessness was assessed using a visual analog scale (VAS) and the forced expiratory volume in 1 s (FEV1) was measured. The relationship between VAS scores and FEV1 and the slope of the regression line of VAS scores on the corresponding FEV1 (VAS/FEV1 slope) were analyzed for each agonist. Subjects without corticosteroids had good perception of methacholine but poor perception of bradykinin-induced bronchoconstriction. In subjects with corticosteroids, bronchoconstriction was well perceived whatever the agonist. VAS/FEV1 slopes for bradykinin but not for methacholine correlated negatively with the magnitude of eosinophilic inflammation in airway mucosa. VAS/FEV1 slopes for each agonist correlated positively with the percentage of basement membrane covered by airway epithelium. We conclude that in asthmatic patients perception of bronchoconstriction is related to eosinophilic inflammation and to epithelial damage in airways and that corticosteroid treatment is associated with improved perception of bronchoconstriction induced by bradykinin, a mediator endogenously produced in asthma.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 12
12
icon of scanned page 13
13
icon of scanned page 14
14
icon of scanned page 15
15
icon of scanned page 16
16
icon of scanned page 17
17
icon of scanned page 18
18
icon of scanned page 19
19
icon of scanned page 20
20
icon of scanned page 21
21

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Orehek J, Beaupré A, Badier M, Nicoli MM, Delpierre S. Perception of airway tone by asthmatic patients. Bull Eur Physiopathol Respir. 1982 Jul-Aug;18(4):601–607. [PubMed] [Google Scholar]
  • Rubinfeld AR, Pain MC. Perception of asthma. Lancet. 1976 Apr 24;1(7965):882–884. [PubMed] [Google Scholar]
  • Burdon JG, Juniper EF, Killian KJ, Hargreave FE, Campbell EJ. The perception of breathlessness in asthma. Am Rev Respir Dis. 1982 Nov;126(5):825–828. [PubMed] [Google Scholar]
  • Peiffer C, Marsac J, Lockhart A. Chronobiological study of the relationship between dyspnoea and airway obstruction in symptomatic asthmatic subjects. Clin Sci (Lond) 1989 Sep;77(3):237–244. [PubMed] [Google Scholar]
  • Sears MR, Rea HH. Patients at risk for dying of asthma: New Zealand experience. J Allergy Clin Immunol. 1987 Sep;80(3 Pt 2):477–481. [PubMed] [Google Scholar]
  • Ruffin RE, Latimer KM, Schembri DA. Longitudinal study of near fatal asthma. Chest. 1991 Jan;99(1):77–83. [PubMed] [Google Scholar]
  • Kikuchi Y, Okabe S, Tamura G, Hida W, Homma M, Shirato K, Takishima T. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med. 1994 May 12;330(19):1329–1334. [PubMed] [Google Scholar]
  • Lougheed MD, Lam M, Forkert L, Webb KA, O'Donnell DE. Breathlessness during acute bronchoconstriction in asthma. Pathophysiologic mechanisms. Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1452–1459. [PubMed] [Google Scholar]
  • Turcotte H, Corbeil F, Boulet LP. Perception of breathlessness during bronchoconstriction induced by antigen, exercise, and histamine challenges. Thorax. 1990 Dec;45(12):914–918.[PMC free article] [PubMed] [Google Scholar]
  • Turcotte H, Boulet LP. Perception of breathlessness during early and late asthmatic responses. Am Rev Respir Dis. 1993 Aug;148(2):514–518. [PubMed] [Google Scholar]
  • Djukanović R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, Howarth RH, Holgate ST. Mucosal inflammation in asthma. Am Rev Respir Dis. 1990 Aug;142(2):434–457. [PubMed] [Google Scholar]
  • Wardlaw AJ, Dunnette S, Gleich GJ, Collins JV, Kay AB. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis. 1988 Jan;137(1):62–69. [PubMed] [Google Scholar]
  • De Monchy JG, Kauffman HF, Venge P, Koëter GH, Jansen HM, Sluiter HJ, De Vries K. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis. 1985 Mar;131(3):373–376. [PubMed] [Google Scholar]
  • Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990 Oct 11;323(15):1033–1039. [PubMed] [Google Scholar]
  • Barnes PJ. Bradykinin and asthma. Thorax. 1992 Nov;47(11):979–983.[PMC free article] [PubMed] [Google Scholar]
  • Kaufman MP, Coleridge HM, Coleridge JC, Baker DG. Bradykinin stimulates afferent vagal C-fibers in intrapulmonary airways of dogs. J Appl Physiol Respir Environ Exerc Physiol. 1980 Mar;48(3):511–517. [PubMed] [Google Scholar]
  • Fuller RW, Dixon CM, Cuss FM, Barnes PJ. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis. 1987 Jan;135(1):176–180. [PubMed] [Google Scholar]
  • Miura M, Belvisi MG, Barnes PJ. Effect of bradykinin on airway neural responses in vitro. J Appl Physiol (1985) 1992 Oct;73(4):1537–1541. [PubMed] [Google Scholar]
  • Christiansen SC, Proud D, Cochrane CG. Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects. J Clin Invest. 1987 Jan;79(1):188–197.[PMC free article] [PubMed] [Google Scholar]
  • Guidelines for standardization of bronchial challenges with (nonspecific) bronchoconstricting agents. Bull Eur Physiopathol Respir. 1983 Sep-Oct;19(5):495–514. [PubMed] [Google Scholar]
  • Polosa R, Holgate ST. Comparative airway response to inhaled bradykinin, kallidin, and [des-Arg9]bradykinin in normal and asthmatic subjects. Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1367–1371. [PubMed] [Google Scholar]
  • Stark RD, Gambles SA, Chatterjee SS. An exercise test to assess clinical dyspnoea: estimation of reproducibility and sensitivity. Br J Dis Chest. 1982 Jul;76(3):269–278. [PubMed] [Google Scholar]
  • Gift AG, Plaut SM, Jacox A. Psychologic and physiologic factors related to dyspnea in subjects with chronic obstructive pulmonary disease. Heart Lung. 1986 Nov;15(6):595–601. [PubMed] [Google Scholar]
  • Noseda A, Schmerber J, Prigogine T, Yernault JC. How do patients with either asthma or COPD perceive acute bronchodilation? Eur Respir J. 1993 May;6(5):636–644. [PubMed] [Google Scholar]
  • Cockcroft A, Guz A. Breathlessness. Postgrad Med J. 1987 Aug;63(742):637–641.[PMC free article] [PubMed] [Google Scholar]
  • CAMPBELL EJ, HOWELL JB. The sensation of breathlessness. Br Med Bull. 1963 Jan;19:36–40. [PubMed] [Google Scholar]
  • Puddy A, Giesbrecht G, Sanii R, Younes M. Mechanism of detection of resistive loads in conscious humans. J Appl Physiol (1985) 1992 Jun;72(6):2267–2270. [PubMed] [Google Scholar]
  • Karlsson JA, Sant'Ambrogio G, Widdicombe J. Afferent neural pathways in cough and reflex bronchoconstriction. J Appl Physiol (1985) 1988 Sep;65(3):1007–1023. [PubMed] [Google Scholar]
  • Sant'Ambrogio G. Nervous receptors of the tracheobronchial tree. Annu Rev Physiol. 1987;49:611–627. [PubMed] [Google Scholar]
  • McFadden ER, Jr, Kiser R, DeGroot WJ. Acute bronchial asthma. Relations between clinical and physiologic manifestations. N Engl J Med. 1973 Feb 1;288(5):221–225. [PubMed] [Google Scholar]
  • Barnes PJ. Neural control of human airways in health and disease. Am Rev Respir Dis. 1986 Dec;134(6):1289–1314. [PubMed] [Google Scholar]
  • Shioya T, Solway J, Munoz NM, Mack M, Leff AR. Distribution of airway contractile responses within the major diameter bronchi during exogenous bronchoconstriction. Am Rev Respir Dis. 1987 May;135(5):1105–1111. [PubMed] [Google Scholar]
  • Mak JC, Barnes PJ. Autoradiographic visualization of bradykinin receptors in human and guinea pig lung. Eur J Pharmacol. 1991 Feb 26;194(1):37–43. [PubMed] [Google Scholar]
  • Molimard M, Martin CA, Naline E, Hirsch A, Advenier C. Contractile effects of bradykinin on the isolated human small bronchus. Am J Respir Crit Care Med. 1994 Jan;149(1):123–127. [PubMed] [Google Scholar]
  • Dixon CM, Barnes PJ. Bradykinin-induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate. Br J Clin Pharmacol. 1989 Jun;27(6):831–836.[PMC free article] [PubMed] [Google Scholar]
  • Ichinose M, Nakajima N, Takahashi T, Yamauchi H, Inoue H, Takishima T. Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet. 1992 Nov 21;340(8830):1248–1251. [PubMed] [Google Scholar]
  • Corfield DR, Webber SE, Hanafi Z, Widdicombe JG. The actions of bradykinin and lys-bradykinin on tracheal blood flow and smooth muscle in anaesthetized sheep. Pulm Pharmacol. 1991;4(2):85–90. [PubMed] [Google Scholar]
  • Ichinose M, Barnes PJ. Bradykinin-induced airway microvascular leakage and bronchoconstriction are mediated via a bradykinin B2 receptor. Am Rev Respir Dis. 1990 Nov;142(5):1104–1107. [PubMed] [Google Scholar]
  • Baraniuk JN, Lundgren JD, Mizoguchi H, Peden D, Gawin A, Merida M, Shelhamer JH, Kaliner MA. Bradykinin and respiratory mucous membranes. Analysis of bradykinin binding site distribution and secretory responses in vitro and in vivo. Am Rev Respir Dis. 1990 Mar;141(3):706–714. [PubMed] [Google Scholar]
  • Fredens K, Dahl R, Venge P. The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. J Allergy Clin Immunol. 1982 Nov;70(5):361–366. [PubMed] [Google Scholar]
  • Durack DT, Ackerman SJ, Loegering DA, Gleich GJ. Purification of human eosinophil-derived neurotoxin. Proc Natl Acad Sci U S A. 1981 Aug;78(8):5165–5169.[PMC free article] [PubMed] [Google Scholar]
  • Fredens K, Tøttrup A, Kristensen IB, Dahl R, Jacobsen NO, Funch-Jensen P, Thommesen P. Severe destruction of esophageal nerves in a patient with achalasia secondary to gastric cancer. A possible role of eosinophil neurotoxic proteins. Dig Dis Sci. 1989 Feb;34(2):297–303. [PubMed] [Google Scholar]
  • Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol. 1992 Jul;90(1):32–42. [PubMed] [Google Scholar]
  • Gleich GJ. The eosinophil and bronchial asthma: current understanding. J Allergy Clin Immunol. 1990 Feb;85(2):422–436. [PubMed] [Google Scholar]
  • Christiansen SC, Proud D, Sarnoff RB, Juergens U, Cochrane CG, Zuraw BL. Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):900–905. [PubMed] [Google Scholar]
Service de Pneumologie, Université René Descartes, Paris, France.
Service de Pneumologie, Université René Descartes, Paris, France.
Copyright notice
Abstract
We studied the perception of bronchoconstriction in asthmatic subjects who were randomly treated with inhaled beta 2 agonist given either alone (n = 9) or associated with inhaled corticosteroids (n = 9). Methacholine and bradykinin challenges, bronchoalveolar lavage, and bronchial biopsies were performed in all subjects. After each dose of agonist, breathlessness was assessed using a visual analog scale (VAS) and the forced expiratory volume in 1 s (FEV1) was measured. The relationship between VAS scores and FEV1 and the slope of the regression line of VAS scores on the corresponding FEV1 (VAS/FEV1 slope) were analyzed for each agonist. Subjects without corticosteroids had good perception of methacholine but poor perception of bradykinin-induced bronchoconstriction. In subjects with corticosteroids, bronchoconstriction was well perceived whatever the agonist. VAS/FEV1 slopes for bradykinin but not for methacholine correlated negatively with the magnitude of eosinophilic inflammation in airway mucosa. VAS/FEV1 slopes for each agonist correlated positively with the percentage of basement membrane covered by airway epithelium. We conclude that in asthmatic patients perception of bronchoconstriction is related to eosinophilic inflammation and to epithelial damage in airways and that corticosteroid treatment is associated with improved perception of bronchoconstriction induced by bradykinin, a mediator endogenously produced in asthma.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.